Mount Sinai Hospital in New York City is the first hospital in the country to offer an innovative new treatment for patients with inoperable and difficult-to-treat liver cancer. The treatment involves injecting patients with luminescent chemotherapy-filled beads, which allows physicians to target tumors with more precision.
The treatment uses M1 LUMI bead technology. Interventional radiologists thread the beads into the blood vessels that lead to the tumor using a catheter. Because the beads are luminescent, physicians can see exactly where the beads are and make sure they are blocking the blood flow feeding the tumor, causing it to shrink.
The minimally invasive, radiopaque treatment is a "game-changer," according to Edward Kim, MD, director of interventional oncology and associate professor of radiology and surgery at The Mount Sinai Hospital.
"In the past, we had no way to verify where the beads were placed in the blood vessels or whether they remained in the intended location over time. Now we can see the location, and adjust if a portion of the tumor has been missed while the patient is on the table without repeating the procedure," said Dr. Kim. "This is what we call precision targeting of tumors."
To learn more about the M1 LUMI bead technology, watch the video below.
More articles on cancer care:
Joe Biden names Greg Simon to lead cancer 'moonshot'
The race to create liquid biopsies for cancer detection continues: 5 things to know
Tumor paint: How one physician is changing cancer treatment